Clinical Trial Detail

NCT ID NCT01248247
Title BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center|AstraZeneca|Bayer|Merck Sharp & Dohme Corp.|National Cancer Institute (NCI)|OSI Pharmaceutic
Indications

lung non-small cell carcinoma

Therapies

Erlotinib

MK2206 + Selumetinib

Sorafenib

Erlotinib + MK2206

Age Groups: adult

No variant requirements are available.